IL92523A - Antiviral preparations containing the history of flavonoid and naringenin, ANR initiator and ginkgo biloba extract - Google Patents
Antiviral preparations containing the history of flavonoid and naringenin, ANR initiator and ginkgo biloba extractInfo
- Publication number
- IL92523A IL92523A IL9252389A IL9252389A IL92523A IL 92523 A IL92523 A IL 92523A IL 9252389 A IL9252389 A IL 9252389A IL 9252389 A IL9252389 A IL 9252389A IL 92523 A IL92523 A IL 92523A
- Authority
- IL
- Israel
- Prior art keywords
- substances
- rna
- pharmaceutical composition
- dosage unit
- flavopereirine
- Prior art date
Links
- 244000194101 Ginkgo biloba Species 0.000 title claims abstract description 8
- 239000003999 initiator Substances 0.000 title claims description 7
- 239000000284 extract Substances 0.000 title claims description 6
- 239000000203 mixture Substances 0.000 title claims description 4
- BAALMEGRQMMBJQ-UHFFFAOYSA-N Flavopereirine Natural products N1=C2C=CC=CC2=C2C1=C1C=CC(CC)=CN1C=C2 BAALMEGRQMMBJQ-UHFFFAOYSA-N 0.000 title abstract description 5
- 230000000840 anti-viral effect Effects 0.000 title description 6
- 150000002795 naringenin derivatives Chemical class 0.000 title description 2
- BAALMEGRQMMBJQ-UHFFFAOYSA-O 3-ethyl-12h-indolo[2,3-a]quinolizin-5-ium Chemical compound N1C2=CC=CC=C2C2=C1C1=CC=C(CC)C=[N+]1C=C2 BAALMEGRQMMBJQ-UHFFFAOYSA-O 0.000 title 1
- 235000008100 Ginkgo biloba Nutrition 0.000 title 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 claims abstract description 12
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000007625 naringenin Nutrition 0.000 claims abstract description 12
- 229940117954 naringenin Drugs 0.000 claims abstract description 12
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 claims abstract description 11
- 208000030507 AIDS Diseases 0.000 claims abstract description 11
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 claims abstract description 11
- 229930019673 naringin Natural products 0.000 claims abstract description 11
- 229940052490 naringin Drugs 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 150000002148 esters Chemical class 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 3
- 239000000126 substance Substances 0.000 claims description 43
- 230000001093 anti-cancer Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 10
- 239000012634 fragment Substances 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000003612 virological effect Effects 0.000 abstract description 5
- MGHKUXYLAVTETL-UHFFFAOYSA-N 3-ethyl-12h-indolo[2,3-a]quinolizin-5-ium;chloride Chemical compound [Cl-].N1C2=CC=CC=C2C2=C1C1=CC=C(CC)C=[N+]1C=C2 MGHKUXYLAVTETL-UHFFFAOYSA-N 0.000 abstract description 4
- 238000000605 extraction Methods 0.000 abstract description 3
- 230000010076 replication Effects 0.000 abstract description 3
- DAGPUIPHACXCSU-UHFFFAOYSA-O 3-ethyl-7,12-dihydro-6h-indolo[2,3-a]quinolizin-5-ium Chemical compound N1C2=CC=CC=C2C2=C1C1=CC=C(CC)C=[N+]1CC2 DAGPUIPHACXCSU-UHFFFAOYSA-O 0.000 abstract description 2
- 230000007062 hydrolysis Effects 0.000 abstract description 2
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 abstract description 2
- 239000013616 RNA primer Substances 0.000 abstract 1
- 229930013930 alkaloid Natural products 0.000 abstract 1
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract 1
- 239000013615 primer Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 23
- 241000700605 Viruses Species 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 3
- 241000450599 DNA viruses Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000723873 Tobacco mosaic virus Species 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229930003949 flavanone Natural products 0.000 description 2
- 235000011981 flavanones Nutrition 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 241000208327 Apocynaceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000037088 Chromosome Breakage Diseases 0.000 description 1
- 241000223782 Ciliophora Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000004062 Tumor Virus Infections Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- YTAQZPGBTPDBPW-UHFFFAOYSA-N flavonoid group Chemical class O1C(C(C(=O)C2=CC=CC=C12)=O)C1=CC=CC=C1 YTAQZPGBTPDBPW-UHFFFAOYSA-N 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000031689 negative regulation of reverse transcription Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000007484 viral process Effects 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8815845A FR2639830B1 (fr) | 1988-12-02 | 1988-12-02 | Composition antivirale et ses applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL92523A0 IL92523A0 (en) | 1990-08-31 |
| IL92523A true IL92523A (en) | 1994-05-30 |
Family
ID=9372531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9252389A IL92523A (en) | 1988-12-02 | 1989-12-01 | Antiviral preparations containing the history of flavonoid and naringenin, ANR initiator and ginkgo biloba extract |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0373986B1 (de) |
| JP (1) | JPH0737393B2 (de) |
| AT (1) | ATE94072T1 (de) |
| DE (1) | DE68909019T2 (de) |
| DK (1) | DK608089A (de) |
| ES (1) | ES2059803T3 (de) |
| FR (1) | FR2639830B1 (de) |
| IL (1) | IL92523A (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02270824A (ja) * | 1989-04-13 | 1990-11-05 | Snow Brand Milk Prod Co Ltd | 逆転写酵素阻害剤 |
| DE4105570A1 (de) * | 1991-02-22 | 1992-08-27 | Helmut Dr Med Scholle | Verwendung eines bakterien- und eiweissfreien filtrats |
| DE4208868A1 (de) * | 1992-03-04 | 1993-09-09 | Michaelis Peter Dr Med | Verwendung eines arzneimittels zur behandlung von metastatischen krebserkrankungen |
| FR2694693B1 (fr) * | 1992-07-28 | 1994-10-28 | Abrax Bio Labs Sa | Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH. |
| DE4308443C2 (de) * | 1993-03-17 | 1996-09-19 | Laves Hans Georg | Arzneimittel zur Behandlung von Retrovirusinfektionen |
| CA2375647A1 (en) * | 1999-07-08 | 2001-01-18 | Patrick T. Prendergast | Use of flavones, coumarins and related compounds to treat infections |
| KR100417172B1 (ko) * | 2000-08-04 | 2004-02-05 | 주식회사 안지오랩 | 은행엽 엑스를 유효성분으로 하는 혈관신생 억제제 |
| WO2005112964A1 (en) * | 2004-05-19 | 2005-12-01 | Natural Source International | Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer |
| CN107501224B (zh) * | 2017-09-12 | 2021-01-19 | 临沂金卓生物科技有限公司 | 一种沸石分子筛催化水解银杏黄酮糖苷生产黄酮苷元的方法 |
| WO2019191776A1 (en) * | 2018-03-31 | 2019-10-03 | Hall John L | Selective anti-cancer agent effective for prevention and treatment |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2450607A2 (fr) * | 1978-03-13 | 1980-10-03 | Beljanski Mirko | Composition pharmaceutique contenant comme principe actif la flavopereine |
| ATE15971T1 (de) * | 1981-03-11 | 1985-10-15 | Mirko Beljanski | Serpentin, alstonin und sempervirin, medikamente, die die tumor- und krebszellen spezifisch hemmen. |
-
1988
- 1988-12-02 FR FR8815845A patent/FR2639830B1/fr not_active Expired - Lifetime
-
1989
- 1989-11-17 EP EP89403176A patent/EP0373986B1/de not_active Expired - Lifetime
- 1989-11-17 ES ES89403176T patent/ES2059803T3/es not_active Expired - Lifetime
- 1989-11-17 DE DE89403176T patent/DE68909019T2/de not_active Expired - Fee Related
- 1989-11-17 AT AT89403176T patent/ATE94072T1/de not_active IP Right Cessation
- 1989-12-01 DK DK608089A patent/DK608089A/da not_active Application Discontinuation
- 1989-12-01 IL IL9252389A patent/IL92523A/en not_active IP Right Cessation
- 1989-12-01 JP JP1310818A patent/JPH0737393B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE68909019T2 (de) | 1994-03-17 |
| EP0373986B1 (de) | 1993-09-08 |
| EP0373986A1 (de) | 1990-06-20 |
| JPH0737393B2 (ja) | 1995-04-26 |
| DE68909019D1 (de) | 1993-10-14 |
| JPH02184632A (ja) | 1990-07-19 |
| ES2059803T3 (es) | 1994-11-16 |
| DK608089D0 (da) | 1989-12-01 |
| DK608089A (da) | 1990-06-03 |
| ATE94072T1 (de) | 1993-09-15 |
| IL92523A0 (en) | 1990-08-31 |
| FR2639830A1 (fr) | 1990-06-08 |
| FR2639830B1 (fr) | 1991-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2656938B2 (ja) | ｄｓＲＮＡと逆転写酵素インヒビターを含んで成るＨＩＶ感染治療のための医薬組成物 | |
| US5145839A (en) | Pharmaceutical composition and method of use | |
| US5908857A (en) | Agent for the treatment of infections | |
| JPH0125A (ja) | ｄｓＲＮＡと逆転写酵素インヒビターを含んで成るＨＩＶ感染治療のための医薬組成物 | |
| IL92523A (en) | Antiviral preparations containing the history of flavonoid and naringenin, ANR initiator and ginkgo biloba extract | |
| US6749870B2 (en) | Compositions and methods for the control of smoking | |
| EP0629400B1 (de) | Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer | |
| WO1990010442A1 (en) | Treatment of acquired immunodeficiency syndrome | |
| DE69726255D1 (de) | Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung | |
| Veterans Administration Cooperative Study Group on Antihypertensive Agents et al. | Captopril: evaluation of low doses, twice-daily doses and the addition of diuretic for the treatment of mild to moderate hypertension | |
| CZ285000B6 (cs) | Antiemetické kompozice | |
| Bocci | The clinical application of ozonetherapy | |
| CA2120001C (en) | Flavopereirine-based pharmaceutical composition and use thereof for treating hiv | |
| Zeidner et al. | Treatment of FeLV-induced immunodeficiency syndrome (FeLV-FAIDS) with controlled release capsular implantation of 2′, 3′-dideoxycytidine | |
| JP3247381B2 (ja) | 抗コレラトキシン剤 | |
| US5955498A (en) | Agent for prophylaxis and therapy of diseases | |
| RU2020972C1 (ru) | Способ лечения невралгии тройничного нерва | |
| RU2538083C1 (ru) | Способ лечения поражения вегетативных парасимпатических узлов головы герпесвирусной этиологии | |
| DE3821392A1 (de) | Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on (ebselen) | |
| RU2162687C2 (ru) | Усовершенствованная лекарственная форма индуктора интерферона | |
| JP2735386B2 (ja) | レトロウイルス感染の治療用医薬 | |
| Harries et al. | Chloroquine-induced pruritus in Nigerian medical and nursing students | |
| JPH0522687B2 (de) | ||
| SU1678375A1 (ru) | Способ лечени иерсиниоза | |
| US7615538B2 (en) | Method for therapy of rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| RH | Patent void | ||
| NE | Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967) | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |